Nifty Alpha Low-Volatility 30 News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of SBI Life Insurance Company Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: SBI Life Insurance Company Ltd.
Rating: 5
Author: Motilal Oswal

Keep track of all breaking news and updates on Nifty Alpha Low-Volatility 30 from all sources in a single place.

Load latest

Lupin Ltd.

24 Jul 2025

1984.60

1.23%

Lupin gets USFDA nod for generic diabetes drugs

Business Line

The company received approval from the USFDA for its abbreviated new drug applications for Liraglutide Injection single-patient-use prefilled pens and glucagon for injection vials, the drug maker said in a statement

Lupin Ltd. is trading above its 50 day SMA of 1956.1

Lupin Ltd.

24 Jul 2025

1984.60

1.23%

Company Update

Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Lupin Receives U.S. FDA Approvals for Liraglutide and Glucagon Injectable Products.

pdf

Dr. Reddy's Laboratories Ltd.

24 Jul 2025

1299.80

0.96%

Dr. Reddy's Shares Spike After Morgan Stanley, BofA Raises Price Target Post Q1 Results

NDTV Profit

The company posted a consolidated net profit of Rs 1,418 crore for the AprilJune period, up just 1.8% year-on-year and below the Rs 1,514 crore consensus estimate.

Dr. Reddy's Laborato.. has an average target of 1278.56 from 9 brokers.

Dr. Reddy's Q1 Results Review: Systematix Maintains 'Hold' Rating On Weak U.S. Performance

NDTV Profit | 24 Jul 2025 9 more

HDFC Bank Ltd.

24 Jul 2025

2021.60

0.65%

Ex-date alert! HDFC Bank, LIC, 52 others to trade ex-dividend on July 25

Business Standard

Here is the complete list of companies that are set to trade ex-dividend on July 25, 2025

Number of MF schemes increased from 668 to 698 in Jun 2025 qtr.

SBI Life Insurance Company Ltd.

24 Jul 2025

1833.40

-0.92%

Product mix shift drives VNB margin expansion

Buy: SBI Life Insurance Company...

Target

Motilal Oswal

SBI Life Insurance (SBILIFE) reported 9% YoY growth in new business APE to INR39.7b (in line). VNB margin for the quarter stood at 27.4% vs our estimate of 28.5% (26.8% in 1QFY25). Absolute VNB grew 12% YoY to INR10.9b (in-line), driven by the product mix shift toward non-linked products.

Number of FII/FPI investors increased from 897 to 946 in Jun 2025 qtr.

HDFC Bank Ltd.

24 Jul 2025

2021.60

0.65%

Coming out of consolidation!

Buy: HDFC Bank Ltd.

Motilal Oswal

HDFC Bank’s (HDFCB) annual report highlights the bank’s focus on sustainable growth over the medium term as it continues to invest in strengthening its physical infrastructure and digital capabilities.

HDFC Bank Ltd. has an average target of 2258.78 from 10 brokers.

Bajaj Finance Ltd.

24 Jul 2025

886.55

0.69%

Stable core amid MSME headwinds; caution to rule the roost

Neutral: Bajaj Finance Ltd.

Motilal Oswal

Bajaj Finance’s (BAF) PAT grew 22% YoY to ~INR47.6b in 1QFY26 (in line). The company’s 1QFY26 NII grew 22% YoY to ~INR102.2b (in line). Non-interest income stood at ~INR23.8b (up 16% YoY), aided by higher income from investments in mutual funds.

Bajaj Finance Ltd. is trading above its 200 day SMA of 818.7

Dr. Reddy's Laboratories Ltd.

24 Jul 2025

1299.80

0.96%

Dr. Reddy's Laboratories (DRRD IN) Q1FY26 Result Update ...

Sell: Dr. Reddy's Laboratories Ltd.

Target

Prabhudas Lilladhar

Dr. Reddy's (DRRD) Q1FY26 EBITDA adjusted for licensing income was in line with our estimate. The base business margins and US sales ex of gRevlimid continued to remain weak. We have scale up base business margins from the current level of 15-16% to +21-22% in FY27E. Our FY26 and FY27E EPS broadly remain unchanged. DRRD have been investing cash flow from gRevlimid to build pipeline across peptides, biosimilars and GLP products; benefits of that may take some time. Further thin US pipeline in near term and competition in...

Number of FII/FPI investors increased from 911 to 917 in Jun 2025 qtr.

Infosys Ltd.

24 Jul 2025

1513.70

-0.15%

Infosys (INFO IN) Q1FY26 Result Update Strong performance,...

Accumulate: Infosys Ltd.

Recommendation Target

Prabhudas Lilladhar

Strong large deal wins of USD 3.8 bn compared to USD 2.6 bn in Q4 The revenue growth performance (+2.6% CC QoQ) was above our estimates (+2.2% QoQ CC), attributed to broad-based growth in verticals and geographies. The BFS strength continued through this quarter as well, the mega deal within the segment further validates the healthy momentum in the vertical. The pockets outside BFS also reported positive growth, however the...

Prabhudas Lilladhar downgraded Infosys Ltd. to Accumulate with a price target of 1750.0 on 24 Jul, 2025.

Infosys Ltd.

24 Jul 2025

1513.70

-0.15%

Infosys: Q1FY26 Result Review

Buy: Infosys Ltd.

Recommendation Target

IDBI Capital

Infosys began it's first quarter with solid momentum, achieving 2.6% sequential and 3.8%YoY revenue growth in constant currency, driven by consistent performance across sectors and regions. Large deal wins reached USD 3.8bn, a 46% rise from the previous quarter, with 55% of the deals being net new, largely supported by vendor consolidation and strong demand for AI-led services. The company has deployed over 300 enterprise AI agents across various business areas, enhancing client productivity, decision-making, and operational efficiency. Despite headwinds from wage hikes and increased variable pay, Infosys...

Infosys Ltd. is trading below all available SMAs

Nifty Alpha Low-Volatility 30 PB	5.8
Nifty Alpha Low-Volatility 30 PE	33.7
Nifty Alpha Low-Volatility 30 DIV	1.1
Nifty Alpha Low-Volatility 30 EPS	785.4